PMID- 38157016
OWN - NLM
STAT- MEDLINE
DCOM- 20240220
LR  - 20240222
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Print)
IS  - 0179-7158 (Linking)
VI  - 200
IP  - 3
DP  - 2024 Mar
TI  - Stereotactic body radiotherapy (SBRT) re-irradiation for local failures following 
      radical prostatectomy and post-operative radiotherapy.
PG  - 230-238
LID - 10.1007/s00066-023-02187-2 [doi]
AB  - PURPOSE: Local recurrences after radical prostatectomy (RP) and postoperative 
      radiotherapy (RT) are challenging for salvage treatment. Retrospective analysis 
      of own experiences with salvage re-irradiation was performed. METHODS: The study 
      included all consecutive patients treated with salvage stereotactic body 
      radiotherapy (sSBRT) for prostate bed recurrence following RP and postoperative 
      RT at a single tertiary center between 2014 and 2021. Treatment toxicity defined 
      as the occurrence of CTCAE grade >/= 2 genito-urinary (GU) or gastro-intestinal 
      (GI) adverse events (AEs) was assessed. A PSA response, biochemical control (BC) 
      and overall survival (OS) were also evaluated. RESULTS: The study group included 
      32 patients with a median age of 68 years and a median follow-up of 41 months, 
      treated with CyberKnife (53%) or Linac (47%) sSBRT. Total dose of 33.75-36.25 Gy 
      in five fractions (72%) was applied in the majority of them. Approximately 19% 
      patients reported grade >/= 2 GU AEs both at baseline and at three months, and 
      grade >/= 2 GI toxicity increased from 0% at baseline to 6% at three months after 
      sSBRT. There was some clinically relevant increase in late toxicity with 31% 
      patients reporting late >/= 2 GU, and 12.5% late >/= 2 GI AEs. Two grade 3 AEs were 
      recorded: recto-urinary fistulas. The majority of patients showed a PSA response 
      (91% at one year post-sSBRT). The 3‑year BC was 40% and 3‑year OS was 87%. 
      CONCLUSIONS: Manageable toxicity profile and satisfactory biochemical response 
      suggest that SBRT in patients with local recurrence following RP and 
      postoperative RT might be a salvage option for selected patients.
CI  - (c) 2023. The Author(s).
FAU - Majewski, Wojciech
AU  - Majewski W
AUID- ORCID: 0000-0002-4000-1716
AD  - Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of 
      Oncology, Wybrzeze Armii Krajowej 15, 44-100, Gliwice, Poland. 
      wojciech.majewski@gliwice.nio.gov.pl.
FAU - Miszczyk, Marcin
AU  - Miszczyk M
AUID- ORCID: 0000-0002-4375-0827
AD  - III Department of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie National 
      Research Institute of Oncology, Wybrzeze Armii Krajowej 15, 44-100, Gliwice, 
      Poland.
AD  - Department of Radiation Oncology, Comprehensive Cancer Center, Medical University 
      of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
FAU - Graupner, Donata
AU  - Graupner D
AUID- ORCID: 0009-0009-8275-0422
AD  - III Department of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie National 
      Research Institute of Oncology, Wybrzeze Armii Krajowej 15, 44-100, Gliwice, 
      Poland.
FAU - Goc, Bartlomiej
AU  - Goc B
AUID- ORCID: 0000-0002-6123-6143
AD  - Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of 
      Oncology, Wybrzeze Armii Krajowej 15, 44-100, Gliwice, Poland.
FAU - Goldner, Gregor
AU  - Goldner G
AD  - Department of Radiation Oncology, Comprehensive Cancer Center, Medical University 
      of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
FAU - Napieralska, Aleksandra
AU  - Napieralska A
AUID- ORCID: 0000-0002-7390-9165
AD  - Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of 
      Oncology, Wybrzeze Armii Krajowej 15, 44-100, Gliwice, Poland.
LA  - eng
PT  - Journal Article
DEP - 20231229
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Male
MH  - Humans
MH  - Aged
MH  - *Radiosurgery/adverse effects
MH  - Prostate
MH  - Prostate-Specific Antigen
MH  - *Re-Irradiation/adverse effects
MH  - *Prostatic Neoplasms/radiotherapy/surgery/drug therapy
MH  - Retrospective Studies
MH  - Neoplasm Recurrence, Local/radiotherapy/surgery/etiology
MH  - Prostatectomy
MH  - Salvage Therapy/adverse effects
PMC - PMC10876733
OTO - NOTNLM
OT  - Local failure
OT  - Postprostatectomy
OT  - Prostate cancer
OT  - Reirradiation
OT  - SBRT
OT  - Salvage
COIS- W. Majewski, M. Miszczyk, D. Graupner, B. Goc, G. Goldner and A. Napieralska 
      declare that they have no competing interests.
EDAT- 2024/01/02 11:43
MHDA- 2024/02/20 11:50
PMCR- 2023/12/29
CRDT- 2023/12/29 11:05
PHST- 2023/08/09 00:00 [received]
PHST- 2023/11/26 00:00 [accepted]
PHST- 2024/02/20 11:50 [medline]
PHST- 2024/01/02 11:43 [pubmed]
PHST- 2023/12/29 11:05 [entrez]
PHST- 2023/12/29 00:00 [pmc-release]
AID - 10.1007/s00066-023-02187-2 [pii]
AID - 2187 [pii]
AID - 10.1007/s00066-023-02187-2 [doi]
PST - ppublish
SO  - Strahlenther Onkol. 2024 Mar;200(3):230-238. doi: 10.1007/s00066-023-02187-2. 
      Epub 2023 Dec 29.